top of page

Press Releases & Publications

Read the latest about Targazyme's Awards and our subsidiaries' work in Cancer Supportive Care, Solid Tumors, as well as in Type 1 Diabetes, Graph Verus Host Disease and other Autoimmune Diseases.

TargaZyme News

Dec 15, 2022

20 Business Excellence Awards 2022 by the Silicon Review

Featuring Lynnet Koh, Targazyme Founder and CEO

March 6, 2019

Award Received from the Sexual Medicine Society of North America to Fund a Targazyme TZ101 Study to Reverse Erectile Dysfunction

Nov 2, 2018

Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution - TZ101 Clinical

June 1, 2018

Results of phase 1 clinical trial evaluating efficacy of 3rd party cord blood regulatory T cells for prevention of graft versus host disease.- TZ101 Clinical

Dec 7, 2017

Regulatory T Cells for Prevention of Graft Versus Host Disease - ASH poster - TZ101 Clinical

July 15, 2016

Cancer Research: ST3GAL1-associated transcriptomic program portends poor prognosis in glioblastoma

Aug 20, 2015

Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation

bottom of page